Back to Browse Journals » Journal of Inflammation Research » Volume 3

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

Authors Slobodan M Jankovic

Published 16 March 2010 Volume 2010:3 Pages 25—31


Review by Single-blind

Peer reviewer comments 5

Slobodan M Jankovic

Pharmacology Department, Medical Faculty, University of Kragujevac, Kragujevac, Serbia

Abstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%–15%) or relapsing-remitting (85%–90%) course. The pathological hallmarks of MS are lesions of both white and grey matter in the central nervous system. The onset of the disease is usually around 30 years of age. The patients experience an acute focal neurologic dysfunction which is not characteristic, followed by partial or complete recovery. Acute episodes of neurologic dysfunction with diverse signs and symptoms will then recur throughout the life of a patient, with periods of partial or complete remission and clinical stability in between. Currently, there are several therapeutic options for MS with disease-modifying properties. Immunomodulatory therapy with interferon beta-1b (IFN-β1b) or -1a, glatiramer and natalizumab shows similar efficacy; in a resistant or intolerant patient, the most recently approved therapeutic option is mitoxantrone. IFN-β1b in patients with MS binds to specific receptors on surface of immune cells, changing the expression of several genes and leading to a decrease in quantity of cell-associated adhesion molecules, inhibition of major histocompatibility complex class II expression and reduction in inflammatory cells migration into the central nervous system. After 2 years of treatment, IFN-β1b reduces the risk of development of clinically defined MS from 45% (with placebo) to 28% (with IFN-β1b). It also reduces relapses for 34% (1.31 exacerbations annually with placebo and 0.9 with higher dose of IFN-β1b) and makes 31% more patients relapse-free. In secondary-progressive disease annual rate of progression is 3% lower with IFN-β1b. In recommended doses IFN-β1b causes the following frequent adverse effects: injection site reactions (redness, discoloration, inflammation, pain, necrosis and non-specific reactions), insomnia, influenza-like syndrome, asthenia, headache, myalgia, hypoesthesia, nausea, paresthesia, myasthenia, chills and depression. Efficacy of IFN-β1b in  relapsing-remitting MS is higher than that of IFN-β1a, and similar to the efficacy of glatiramer acetate. These facts promote IFN-β1b as one of the most important drugs in the spectrum of immunological therapies for this debilitating disease.
Keywords: multiple sclerosis, interferon beta 1b, mechanism of action, efficacy, safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion

Stefanini FR, Maia M, Falabella P, Pfister M, Niemeyer M, Kashani AH, Humayun MS, Koss MJ

Clinical Ophthalmology 2014, 8:847-856

Published Date: 6 May 2014

Injectable thermosensitive hydrogel composite with surface-functionalized calcium phosphate as raw materials

Fan RR, Deng XH, Zhou LX, Gao X, Fan M, Wang YL, Guo G

International Journal of Nanomedicine 2014, 9:615-626

Published Date: 21 January 2014

Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy

Flatz L, Conrad C

Psoriasis: Targets and Therapy 2013, 3:1-10

Published Date: 27 February 2013

Different corrosive effects on hydroxyapatite nanocrystals and amine fluoride-based mouthwashes on dental titanium brackets: a comparative in vitro study

Lelli M, Marchisio O, Foltran I, Genovesi A, Montebugnoli G, Marcaccio M, Covani U, Roveri N

International Journal of Nanomedicine 2013, 8:307-314

Published Date: 17 January 2013

Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B

Thomas Scior, José Antonio Guevara-García, FJ Melendez, et al

Drug Design, Development and Therapy 2010, 4:231-242

Published Date: 23 September 2010

Management of tinea capitis in childhood

Antoni Bennassar, Ramon Grimalt

Clinical, Cosmetic and Investigational Dermatology 2010, 3:89-98

Published Date: 14 July 2010

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia

Louise Profit

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

Bortezomib: the evidence of its clinical impact in multiple myeloma

Simon Lancaster

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006